Showing results (121-130 of 175) with videos related to
Sort By:
Pageof 18
Cancer|March 1, 1994
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group studyG P Sutton, J A Blessing, H D Homesley, et al.Cancer|May 15, 1980
Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycinR C Park, J Blom, P J Disaia, et al.Gynecologic Oncology|February 1, 1995
Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trialP S Braly, J S Berek, J A Blessing, et al.Annals of Internal Medicine|July 1, 1989
Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology GroupS D Williams, J A Blessing, D H Moore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1989
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group StudyG P Sutton, J A Blessing, H D Homesley, et al.Seminars in Oncology|February 1, 1989
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studiesG P Sutton, J A Blessing, G Photopulos, et al.Gynecologic Oncology|February 1, 1989
A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group studyJ T Thigpen, J A Blessing, P J DiSaia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group StudyW P McGuire, J A Blessing, M A Bookman, et al.American Journal of Clinical Oncology|June 1, 1992
Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin. A phase I study of the Gynecologic Oncology GroupG A Omura, J L Hubbard, K D Hatch, et al.Obstetrics and Gynecology|March 1, 1989
A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group studyS L Curry, J A Blessing, P J DiSaia, et al.Pageof 18